Upon infection from respiratory viruses such as influenza A and SARS-associated coronavirus, bronchial epithelial cells and alveolar epithelial cells produce and release cytokines and chemokines. Coronaviruses like SARS are known to replicate in human airway cells, making airway epithelial cells an important target for these types of diseases. Researchers, as a result, have suggested that one potential way to enhance response to lung infections is to boost epithelial cell immunity. Understanding more about the role of airway epithelial cells in disease pathogenesis will provide new avenues for treatment of acute respiratory infections, such as COVID-19.
Innoprot offers a wide range of human and animal airway primary cells, inlcuding alveolar and bronchial epithelial cells.